LCZ696 in Advanced LV Hypertrophy and HFpEF
Sacubitril/Valsartan (LCZ696) in Patients With Advanced Hypertensive Left Ventricular Hypertrophy and Heart Failure With Preserved Ejection Fraction: Clinical, Haemodynamic and Neurohumoral Effects (a Phase 2, Randomized, Single-center, Parallel Group Study)
Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
This PHASE2 trial investigates Essential Hypertension and Heart Failure and is currently completed. National Medical Research Center for Cardiology, Ministry of Health of Russian Federation leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Unknown → Completed
-
Feb 2025 — Jun 2025 [monthly]
Unknown PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
▶ Show 7 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Feb 2022 — Feb 2024 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jan 2022 — Feb 2022 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jul 2019 — Jan 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2019 — Jul 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
For direct contact, visit the study record on ClinicalTrials.gov .